[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592899":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":48,"centralContacts":52,"locations":62,"responsibleParty":77,"collaborators":80,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":39,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":39,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":109,"overallStatus":65,"whyStopped":39,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Yale University","OTHER",[8,16,21,24,27,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Control","ACTIVE_COMPARATOR","n = 30 - up to three PET scanning sessions.",[13,14,15],"Drug: [ 18F]3F4AP","Drug: [18F]MK6240","Drug: [11C]PIB",{"label":17,"type":18,"description":19,"interventionNames":20},"Alzheimer's Disease (AD)","EXPERIMENTAL","n = 15 - up to three PET scanning sessions.",[13,14,15],{"label":22,"type":18,"description":19,"interventionNames":23},"Mild Cognitive Impairment (MCI)",[13,14,15],{"label":25,"type":18,"description":19,"interventionNames":26},"Multiple Sclerosis (MS)",[13,14,15],{"label":28,"type":18,"description":19,"interventionNames":29},"Spinal Cord Injury (SCI)",[13,14,15],{"label":31,"type":18,"description":19,"interventionNames":32},"Spinal radiculopathy (SR)",[13,14,15],[34,40,44],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","[ 18F]3F4AP","PET Scan #3",[17,9,22,25,28,31],null,{"type":35,"name":41,"description":42,"armGroupLabels":43,"otherNames":39},"[18F]MK6240","PET Scan #2",[17,9,22,25,28,31],{"type":35,"name":45,"description":46,"armGroupLabels":47,"otherNames":39},"[11C]PIB","PET Scan #1",[17,9,22,25,28,31],[49],{"name":50,"affiliation":5,"role":51},"Georges El Fakhri, PhD, DABR","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":39,"email":57},"Shannan Henry","CONTACT","+1 (203) 737-5278","shannan.henry@yale.edu",{"name":59,"role":55,"phone":60,"phoneExt":39,"email":61},"Kayla Cottiers","203-737-7496","kayla.cottiers@yale.edu",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":39},"Yale University PET Center","RECRUITING","New Haven","Connecticut","06510","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-72.92816,41.30815,{"lat":75,"lon":74},{"type":51,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"Georges El Fakhri","Professor of Radiology and Biomedical Imaging and of Biomedical Informatics & Data Science",[81,84],{"name":82,"class":83},"National Institute for Biomedical Imaging and Bioengineering (NIBIB)","NIH",{"name":85,"class":83},"National Institute on Aging (NIA)","100592899","phase-1-exploring-the-utility-of-18f3f4ap-for-demyelination-imaging-100592899",false,"NCT06999434","Exploring the Utility of [18F]3F4AP for Demyelination Imaging","Inclusion:\n\n1. Male and Female subjects must be ≥18 and \\\u003C90 years of age;\n2. Able to understand and provide informed consent prior to study procedures\n3. Must be in good health\n\nExclusion:\n\n1. Less than 18 years of age;\n2. Pregnant or breastfeeding;\n3. Any significant systemic illness or unstable medical condition;\n4. Pre-existing medical conditions or claustrophobic reactions;\n5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);\n6. History of a bleeding disorder or are currently taking anticoagulants.",true,"ALL","18 Years","90 Years",{"count":97,"type":98},105,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","The overall objective is to obtain an assessment of the pharmacokinetics of \\[18F\\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).",[104,105,17,106,107,108],"Demyelinating Disorders","MCI","MS (Multiple Sclerosis)","SCI - Spinal Cord Injury","Spinal Radiculopathy",[110,104,111,112,113],"3F4AP","MS","SCI","AD","2025-05-22",{"date":116,"type":117},"2025-05-31","ACTUAL",{"date":119,"type":117},"2025-05-05",{"date":121,"type":98},"2030-05-05",{"name":5,"class":6},1]